Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors
For years, Gilead Sciences’ (NASDAQ:GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company’s revenues have experienced an enormous decline from 2015 onwards, falling over $10 billion in the past four years as patients cured of …
News story posted on 2020-04-16T17:43:00.0000000Z
